Business
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds 100% diabetic wound c...
About this update from Kane Biotech Inc.
[{"type":"text","content":"Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences\n\n\n\n\n\n Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds\n \n\n\n\n 100% diabetic wound closure in\n \n\n ≤\n \n\n 12 weeks\n \n\n\n\n Preclinical sustained antibiofilm activity for a minimum of 7 days\n \n\n\n\n\n\n WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve\n \n ®\n \n Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound infection control. The findings were recently presented at two major U.S. medical meetings: Diabetic Foot Conference (DFCon 2025), held October 23-25 in Anaheim, California, and the Southern Region Burn Conference held October 30-November 2 in Charleston, South Carolina.\n \n\n\n\n\n\n\n US FDA 510(k) cleared revyve\n \n\n\n Antimicrobial Wound Gel and\n \n\n\n revyve Antimicrobial Wound\n \n\n\n Gel Spray\n \n\n\n\n Clinical Data: Outperforming the Standard of Care\n \n\n\n At DFCon 2025, Dr. Raymond Abdo, DPM (St. Louis Foot and Ankle Institute) and Dr. Peter Moyer, DPM (Foot & Ankle Institute of the Carolinas) presented data showing revyve achieved healing outcomes exceeding the current standard of care for diabetic foot ulcers (DFUs):\n \n\n\n 97% average Percent Area Reduction (PAR) in 4 weeks, compared to the 40 – 50% PAR benchmark¹\n \n\n Complete wound closure within 8–12 weeks in all cases across a multi-center series\n \n\n Sustained infection control and reduced bacterial bioburden throughout healing\n \n\n\n\n\n “The usage of revyve gel has helped my patient proceed with increased healing wounds by keeping bacteria and bioburden at bay for hard to heal ulcerations,” said Dr. Abdo.\n \n\n “revyve is a great product for diabetic ulcers. It utilizes advanced skin healing technology to promote faster and more effective wound healing by managing biofilm. revyve has helped manage my diabetic patients with Peripheral Arterial Disease, hemodialysis, and elevated A1c,” said Dr. Moyer.\n \n\n\n Rapid Antimicrobial Efficacy in Burn Care\n \n\n\n At the 2025 Southern Region Burn Confer...